Compare Adaptive Biotechnologies Corp (ADPT) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Modine Manufacturing Company — how do they compare? Adaptive Biotechnologies Corp trades at $20.08 (market cap $3.33B), while Modine Manufacturing Company trades at $227.81 (market cap $12.17B). The key difference: Modine Manufacturing Company is far larger — about 3.7× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals.
| ADPT | MOD | |
|---|---|---|
Market Cap | $3.33B | $12.17B |
Sector | Health | Technology |
52-Week High | $22.37 | $306.89 |
52-Week Low | $10.24 | $90.02 |
Enterprise Value | $3.19B | $12.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Modine (MOD) trades at $235.19, up 1.83% on the day, amid a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $2.58B in 2025, with net income of $184M, though 2026 projections show margin compression. Analyst consensus remains strongly bullish with a $328.80 price target, driven by optimism around its data center cooling business, which is expected to grow 60-80% in FY27 according to Seeking Alpha (2026-06-11).
The outlook is mixed: robust growth in data center demand offers significant upside, but high valuations (P/E 104.07) and near-term technical weakness pose risks. Investors face volatility from supply chain challenges and competitive pressures in the HVAC segment, though institutional support and consistent earnings outperformance provide a foundation for long-term growth if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
